Standout Papers

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis 2012 2026 2016 2021 1.2k
  1. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis (2012)
    Claire Harrison, Jean‐Jacques Kiladjian et al. New England Journal of Medicine
  2. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (2016)
    Claire Harrison, Alessandro M. Vannucchi et al. Leukemia

Immediate Impact

9 from Science/Nature 62 standout
Sub-graph 1 of 21

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Adipose-tissue plasticity in health and disease
2022 Standout
7 intermediate papers

Works of Mari McQuitty being referenced

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
2013
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Mari McQuitty 1625 991 47 1286 11 2.1k
Chris Arthur 1106 151 22 1462 35 1.9k
Hugh D Carr-Smith 357 1085 43 883 14 1.6k
Graham P. Mead 418 1258 108 1061 23 2.0k
K. B. McCredie 434 317 36 1115 49 1.7k
Manuel E. Kaplan 936 538 75 779 53 2.3k
N. C. Allan 1094 121 71 1250 47 2.0k
R.J. Berckmans 287 1265 267 955 23 2.6k
FR Appelbaum 565 245 108 1850 19 2.3k
C.J. Haagsma 444 355 261 839 37 2.8k
Kerry Taylor 1124 257 22 1542 28 2.0k

All Works

Loading papers...

Rankless by CCL
2026